Quest International: Quest Responds to the Surge in FDA Recalls by Strengthening Industry-Leading Field Corrective Action Services
Quest International's Expanded FCA Resources Offer Medical Device OEMs Timely, Reliable Support Amid Rising FDA RecallsIRVINE ...
Business Insider22h
EQS-News: Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
Obefazimod, Abivax’s lead investigational drug candidate, is an orally administered small ... Marchés Financiers pursuant to its legal obligations including its universal registration document ...
manilatimes1d
Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV
A live webcast of the Jefferies fireside chat can be accessed by visiting the Investors section of the Company's website at ...
WBIW1h
Traffic stop for improper license plate lands man in jail on drug and firearm charges
A Bedford man is facing multiple charges after a routine traffic stop led to the discovery of methamphetamine, a firearm, and ...
ZEO ScientifiX and Exotropin Join Forces to Launch a Solution to Address the Growing Unmet Need for Hair Loss
FORT LAUDERDALE, FL / / November 13, 2024 / ZEO ScientifiX, Inc. ('ZEO' or the 'Company') (OTCQB:ZEOX), a South Florida-based clinical-stage biopharmaceutical company, announced it has partnered with ...
Le Lézard23h
Hyperfine, Inc. to Participate in Upcoming Investor Conferences
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system?the ...
Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...
Ocular Therapeutix™ Reports Third Quarter 2024 Results And Business Highlights
SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients d ...
TMCnet22h
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
The strong data and enthusiastic feedback from our advisors, clinical trial investigators, the retina physician community and the FDA support pivotal development ... to support development strategy ...